Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR3 | O14843 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | CES2 | O00748 | 1/20 | 0.31 |
| ▸ | CES1 | P23141 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20000454 | 0.82 | APLNR (0.40) | FFAR3NPSR1MAPTLMNA | |
| SCHEMBL16887593 | 0.82 | TP53 (0.42) | FFAR3NPSR1MAPTALDH1A1 | |
| SCHEMBL16875576 | 0.82 | TP53 (0.42) | FFAR3NPSR1MAPTALDH1A1 | |
| SCHEMBL9044623 | 0.82 | FFAR3 (0.34) | FFAR3NPSR1MAPTCES2CES1 | |
| SCHEMBL595271 | 0.82 | APLNR (0.40) | FFAR3NPSR1MAPTLMNA | |
| SCHEMBL18169491 | 0.82 | APLNR (0.40) | FFAR3NPSR1MAPTLMNA | |
| SCHEMBL16875305 | 0.82 | TP53 (0.42) | FFAR3NPSR1MAPTALDH1A1 | |
| SCHEMBL20855519 | 0.81 | SMN1; SMN2 (0.40) | FFAR3NPSR1MAPTALDH1A1 | |
| SCHEMBL8175853 | 0.78 | FFAR3 (0.50) | FFAR3NPSR1MAPTALDH1A1L3MBTL1 | |
| SCHEMBL283125 | 0.78 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2019063748-A1 | ROR-GAMMA INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2019-04-04 | — | — | WO | disclosed |
| WO-2019063748-A1 | ROR-GAMMA INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2019-04-04 | — | — | WO | disclosed |
| EP-2706853-B1 | AMINOPYRIMIDINES AS SYK INHIBITORS | MERCK SHARP & DOHME (US) | 2017-06-14 | — | — | EP | disclosed |
| US-9290490-B2 | Aminopyrimidines as Syk inhibitors | MERCK SHARP & DOHME CORP. (US) | 2016-03-22 | — | — | US | disclosed |
| US-20140148474-A1 | AMINOPYRIMIDINES AS SYK INHIBITORS | MERCK SHARP & DOHME LLC | 2014-05-29 | — | — | US | disclosed |
| EP-2706853-A1 | AMINOPYRIMIDINES AS SYK INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2014-03-19 | — | — | EP | disclosed |
| CN-103619172-A | Aminopyrimidines as SYK inhibitors | MERCK SHARP & DOHME | 2014-03-05 | — | — | CN | disclosed |
| WO-2012154519-A1 | AMINOPYRIMIDINES AS SYK INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2012-11-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140148474-A1 | AMINOPYRIMIDINES AS SYK INHIBITORS | SYK, BTK, LCK | FFAR3 3585/4885NPSR1 2035/4885MAPT 3941/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.